Tenaya Therapeutics, Inc.

TNYA

$0.69

-0.73%

2026-08-28 16:00:01 EDT-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product ...

Price Action of TNYA

$0.69

-0.73%-$0.01

High—

Low—

52W High-70.6%

Rel. vol—

Interval

Range6.1h

Volume—SMA5SMA10

—

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company dedicated to addressing the underlying drivers of heart disease through innovative therapeutic approaches. Founded in 2016 by leading cardiovascular scientists from the Gladstone Institutes and UT Southwestern Medical Center, the company has established three distinct but interrelated product platforms: Gene ...Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company dedicated to addressing the underlying drivers of heart disease through innovative therapeutic approaches. Founded in 2016 by leading cardiovascular scientists from the Gladstone Institutes and UT Southwestern Medical Center, the company has established three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. These platforms aim to provide potentially curative therapies for rare genetic disorders and more prevalent heart conditions. Business and Products: The company's lead product candidate is TN-201, a gene therapy designed to treat myosin binding protein C3-associated hypertrophic cardiomyopathy (HCM), currently in Phase 1b/2 clinical trials. Another gene therapy, TN-401, targets plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) and is also in Phase 1b/2 development. Additionally, TN-301, a small molecule histone deacetylase-6 inhibitor, is being evaluated for heart failure with preserved ejection fraction (HFpEF) in Phase 1 trials. Tenaya also has a research collaboration with Alnylam Pharmaceuticals to identify and validate novel gene targets for cardiovascular disease. Financial Snapshot: As a clinical-stage company with no approved products, Tenaya currently has no revenue from product sales, with revenue per share of $0.006 (ttm). The company's market capitalization is approximately $160 million, and its stock has traded in a range of $0.532 to $2.35 over the past year. The company's financial metrics indicate significant investment in research and development, with R&D expenses accounting for about 46% of total revenue (though revenue is minimal, this reflects the spend ratio). The company has a current ratio of 4.5, indicating strong liquidity, and holds cash per share of $0.359. However, it is operating at a loss, with a negative net profit margin of -77.24% and negative free cash flow, which is typical for early-stage biotech firms. Key People and Leadership: The company is led by CEO Faraz Ali, who has an MBA and brings extensive experience in the biopharmaceutical industry. Other key leaders include Chief Medical Officer Whit Tingley, M.D., Ph.D., and Chief Technology Officer Kee-Hong Kim, Ph.D. The leadership team comprises seasoned professionals with backgrounds in cardiology, rare disease drug development, and gene therapy. Employees and Operations: Tenaya has approximately 70 full-time employees (as per the latest data), fitting into the 51-200 employee range. The company is headquartered in South San Francisco, California, and was incorporated in 2016. It went public on the NASDAQ exchange in July 2021. Future Outlook: The company is focused on advancing its pipeline through clinical trials and hopes to bring much-needed therapies to patients with heart disease. With a strong scientific foundation and promising product candidates, Tenaya aims to transform the treatment landscape for cardiovascular conditions.ExpandCollapse

Founded

2016

Employees

CEO

Faraz Ali

Full Name

Tenaya Therapeutics, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-108.05%

Market Cap

$0.15B

Current Ratio

4.52

WACC

16.48%

ROIC

-142.33%

Contact Information

https://www.tenayatherapeutics.com

650 825 6900

171 Oyster Point Boulevard, South San Francisco, CA 94080

Key Metrics of TNYA

Snapshot

Latest / TTM · 6 periods

Market Cap

$149.75M

ROCE

-142.1%

EV / EBITDA

-0.80x

-71.1% YoY

FCF Yield

-47.6%

+15.7% YoY

Cash Conversion Cycle

586.2d

Current Ratio

4.52

Quick take

TTM —

Positive CCC

Financial Highlights of TNYA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

263.7%

Net Margin

-7724.0%

P/E Ratio

-1.31x

n/a

Debt / Equity

0.06

n/a

Current Ratio

4.52

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of TNYA

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.10 · Revenue $802500.00 · 5 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.10 · Revenue $2.54M · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.48 · Revenue $4.00M · 4 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.10 · Revenue $1.40M · 3 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $-0.20 · Revenue $1.11M
View filing
May 6, 2026
Q1 FY2026 · Results reported
EPS $-0.09 · Revenue $225000.00
View filing
Mar 11, 2026
FY2025 · Annual results
EPS $-0.59 · Revenue $0.00
View filing
Nov 10, 2025
Q3 FY2025 · Results reported
EPS $-0.12 · Revenue $0.00
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $-0.14 · Revenue $0.00
View filing
May 7, 2025
Q1 FY2025 · Results reported
EPS $-0.24 · Revenue $0.00
View filing

Financial Statements of TNYA

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	+393.3%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-90.6M	+18.5%	-125.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	+114.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	+55.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	+54.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-68.9M	+24.7%	-19.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	+75.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	8.8%	-40.0%	-40.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	6.84x	+62.2%	-21.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$146.9M	+22.5%	-30.7%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.59 vs -0.60	+2.3%	-0.20 vs -0.07	-192.7%
Revenue Surprise	$0 vs $2.1M	-100.0%	$1.1M vs $10.0M	-88.9%

Insider Transactions of TNYA

Acquisitions (A)

Since Jul 13, 2026

Disposals (D)

Since Jul 13, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 17, 2026	Ali Faraz	director, officer: Chief Executive Officer	Common Stock	D	5,837	$0.71
Aug 17, 2026	Ali Faraz	director, officer: Chief Executive Officer	Common Stock	D	3,969	$0.71
Aug 17, 2026	Ali Faraz	director, officer: Chief Executive Officer	Common Stock	D	5,020	$0.71
Aug 17, 2026	Ali Faraz	director, officer: Chief Executive Officer	Common Stock	D	7,406	$0.71
Aug 17, 2026	Tingley Whittemore	officer: Chief Medical Officer	Common Stock	D	1,637	$0.71

Leadership Team of TNYA

13 executives

Name	Title	Compensation	Gender	Year Born	Status
Faraz Ali	President, CEO & Director	USD 983,964	Male	1973	Active
Whittemore G. Tingley	Chief Medical Officer	USD 702,844	—	1968	Active
Deepak Srivastava	Scientific Founder, Chairman of Scientific Advisory Board & Director	USD 90,500	—	1967	Active
Kee-Hong Kim	Chief Technology Officer	—	—	1966	Active
Eric Hyllengren	CFO & Principal Accounting Officer	—	Male	1975	Active
Jennifer Drimmer	General Counsel & Corporate Secretary	—	Female	—	Active
Bruce R. Conklin	Scientific Founder	—	—	—	Active
Saptarsi Haldar	Scientific Founder	—	—	—	Active
Sheng Ding	Scientific Founder	—	—	—	Active
Eric N. Olson	Scientific Founder & Member of Scientific Advisory Board	—	—	—	Active
Tomohiro Higa	Senior Vice President of Finance & Interim Principal Accounting Officer	—	Male	1969	Active
Benoit G. Bruneau	Scientific Founder	—	—	—	Active
Michelle Corral	Vice President of Investor Relationship & Corporate Communications	—	Female	—	Active

Recent News of TNYA

Seeking Alpha8/14/2026Neutral

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

GlobeNewsWire8/5/2026Neutral

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Trial Plans for TN-201 and TN-401 Anticipated in 4Q 2026 TN-301 Advancing toward Phase 2 Trial Start in 2H 2027 $10 million Upfront Payment Received from Alnylam Collaboration Extends Cash Runway Through Q3 2027 SOUTH SAN FRANCISCO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

GlobeNewsWire8/4/2026Neutral

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of management will host 1x1 meetings with investors at the upcoming Canaccord Genuity 46th Annual Growth Conference taking place from August 11-12, 2026 in Boston, Massachusetts.

Globe News Wire7/14/2026Neutral

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.

GlobeNewsWire7/14/2026Neutral

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.

Historical Employee Count of TNYA

Current

Change

-27.84%

Minimum

Maximum

141

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	70	10-K	Mar 11, 2026	View
Dec 31, 2024	97	10-K	Mar 10, 2025	View
Dec 31, 2023	140	10-K	Mar 18, 2024	View
Dec 31, 2022	141	10-K	Mar 8, 2023	View
Dec 31, 2021	106	10-K	Mar 23, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Tenaya Therapeutics, Inc.